ASRT (ASRT)
Drug Manufacturers - Specialty & Generic
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Live quote temporarily unavailable — press releases and news are still shown below.
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Peers in Drug Manufacturers - Specialty & Generic
All in industry →Takeda Pharmaceutical Company Limited
Zoetis Inc.
Haleon plc
Teva Pharmaceutical Industries Limited
United Therapeutics Corporation
Viatris Inc.
Regencell Bioscience Holdings Limited
Neurocrine Biosciences, Inc.
Elanco Animal Health Incorporated
Dr. Reddy's Laboratories Limited
Recent press releases
April 2026
Garda Therapeutics proposes acquiring Assertio stock for $18.00; offer pending
# 📝 What This Document Is 📰 This is an incredibly important filing called a Schedule 14D-9. In simple terms, it is a formal legal statement about a proposed corporate takeover. It is a **Solicitation/Recommendation Statement**, meaning the company is communicating to investors and shareholders th
Assertio Board Recommends Shareholders Accept $18 Per Share Buyout Offer
# 🧾 What This Document Is This is a formal **Solicitation/Recommendation Statement** (a Schedule 14D-9C). Think of it as an official company announcement to its shareholders. Its purpose is to formally state the Board of Directors' recommendation regarding a proposed buyout of the company. It's not
ASRT Recommends $18-Per-Share Tender Offer from Garda
# 📜 What This Document Is This is a **Schedule 14D-9 filing**. It’s a formal document a company files with the SEC when it’s being acquired through a **tender offer**. 👉 **Why it matters:** Its main job is to give shareholders the company’s official **recommendation** on whether to accept the bu
Assertio Annual Report Showcases CAMZYOS Success and Strategy
# 🧾 What This Document Is This is Assertio's Annual Report to Shareholders (ARS). Think of it as the company's yearly "report card" sent directly to its owners. It's a comprehensive overview that combines the formal financial statements (like the 10-K) with a more shareholder-friendly narrative fro
Assertio Holdings, Inc. — DEF 14A Filing
# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)** for **Assertio Holdings, Inc. (ASRT)**. It’s like the official invitation and agenda for the company's **Annual Meeting of Stockholders**, which will be held virtually on **May 5, 2026, at 11:30 a.m. Central Time**. 👉 **
SEC filings
All filings →Insider trades
All insider trades →ASRT has no reported insider trades in the last 90 days.